Thrombocytopenia - Epidemiology Forecast to 2027

  • ID: 4564668
  • Report
  • 143 pages
  • DelveInsight
1 of 3
‘Thrombocytopenia - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Thrombocytopenia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered:
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period:: 2016-2027

Thrombocytopenia Epidemiology

The Thrombocytopenia epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Thrombocytopenia are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Thrombocytopenia Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, prevalent cases by type, prevalent cases by age, prevalent and diagnosed cases of Idiopathic Thrombocytopenic Purpura (ITP), Chemotherapy-Induced Thrombocytopenia (CIT), Heparin-Induced Thrombocytopenia (HIT) and Thrombocytopenia associated with Chronic Liver Disease (CLD)) scenario of Thrombocytopenia in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to this research, the total prevalent population of Thrombocytopenia was found to be 817,855, in the year 2016 in 7MM.

Report Scope:
  • The report covers detailed overview of Thrombocytopenia explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Thrombocytopenia in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by type i.e., Thrombotic Thrombocytopenic Purpura, Idiopathic Thrombocytopenic Purpura, Chemotherapy-Induced Thrombocytopenia, Heparin-Induced Thrombocytopenia and Thrombocytopenia associated with Chronic Liver Disease in 7MM.
Key strengths:
  • 10 Year Forecast of Thrombocytopenia epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Thrombocytopenia
  • Prevalent Cases according to segmentation: Subtype-specific prevalence i.e., Thrombotic Thrombocytopenic Purpura, Idiopathic Thrombocytopenic Purpura, Chemotherapy-Induced Thrombocytopenia, Heparin-Induced Thrombocytopenia and Thrombocytopenia associated with Chronic Liver Disease
  • Diagnosed cases of Thrombocytopenia
Key assessments:
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Key Insights

2. Thrombocytopenia Market Overview at a Glance
2.1. Market Share (%) Distribution of Thrombocytopenia in 2017
2.2. Market Share (%) Distribution of Thrombocytopenia in 2027

3. Disease Background and Overview: Thrombocytopenia
3.1. Introduction
3.2. Causes of Thrombocytopenia
3.3. Pathogenesis
3.4. Pathophysiology
3.5. Etiology
3.6. Symptoms
3.7. Diagnosis and Treatment
3.8. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
3.9. Management of thrombocytopenia
3.10. First Line Therapies
3.11. Second and Third Line Therapies
3.12. Diagnostic and treatment guidelines form thrombotic thrombocytopenic purpura (TTP) 2017 in Japan
3.13. Treatment of Heparin-induced Thrombocytopenia (HIT)

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Prevalent Population of Thrombocytopenia
4.4. Country Wise-Epidemiology of Thrombocytopenia
4.4.1. United States
4.4.1.1. Prevalent cases of Thrombocytopenia in the United States
4.4.1.2. Prevalent cases of Thrombotic Thrombocytopenic Purpura (TTP) by Type in the United States
4.4.1.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in the United States
4.4.1.4. Prevalent cases of Idiopathic Thrombocytopenic Purpura (ITP) in the United States
4.4.1.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in the United States
4.4.1.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in the United States
4.4.1.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in the United States
4.4.1.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in the United States
4.4.1.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in the United States
4.4.1.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in the United States
4.4.1.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in the United States
4.4.1.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in the United States
4.4.2. Germany
4.4.2.1. Prevalent cases of Thrombocytopenia in Germany
4.4.2.2. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Type in Germany
4.4.2.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in Germany
4.4.2.4. Prevalent cases of Idiopathic Thrombocytopenic purpura (ITP) in Germany
4.4.2.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Germany
4.4.2.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in Germany
4.4.2.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Germany
4.4.2.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Germany
4.4.2.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in Germany
4.4.2.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Germany
4.4.2.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in Germany
4.4.2.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Germany
4.4.3. France
4.4.3.1. Prevalent cases of Thrombocytopenia in France
4.4.3.2. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Type in France
4.4.3.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in France
4.4.3.4. Prevalent cases of Idiopathic Thrombocytopenic purpura (ITP) in France
4.4.3.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in France
4.4.3.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in France
4.4.3.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in France
4.4.3.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in France
4.4.3.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in France
4.4.3.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in France
4.4.3.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in France
4.4.3.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in France
4.4.4. Italy
4.4.4.1. Prevalent cases of Thrombocytopenia in Italy
4.4.4.2. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Type in Italy
4.4.4.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in Italy
4.4.4.4. Prevalent cases of Idiopathic Thrombocytopenic purpura (ITP) in Italy
4.4.4.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Italy
4.4.4.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in Italy
4.4.4.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Italy
4.4.4.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Italy
4.4.4.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in Italy
4.4.4.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Italy
4.4.4.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in Italy
4.4.4.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Italy
4.4.5. Spain
4.4.5.1. Prevalent cases of Thrombocytopenia in Spain
4.4.5.2. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Type in Spain
4.4.5.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in Spain
4.4.5.4. Prevalent cases of Idiopathic Thrombocytopenic purpura (ITP) in Spain
4.4.5.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Spain
4.4.5.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in Spain
4.4.5.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Spain
4.4.5.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Spain
4.4.5.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in Spain
4.4.5.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Spain
4.4.5.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in Spain
4.4.5.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Spain
4.4.6. United Kingdom
4.4.6.1. Prevalent cases of Thrombocytopenia in the United Kingdom
4.4.6.2. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Type in the United Kingdom
4.4.6.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in the United Kingdom
4.4.6.4. Prevalent cases of Idiopathic Thrombocytopenic purpura (ITP) in the United Kingdom
4.4.6.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in the United Kingdom
4.4.6.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in the United Kingdom
4.4.6.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in the United Kingdom
4.4.6.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in the United Kingdom
4.4.6.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in the United Kingdom
4.4.6.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in the United Kingdom
4.4.6.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in the United Kingdom
4.4.6.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in the United Kingdom
4.4.7. Japan
4.4.7.1. Prevalent cases of Thrombocytopenia in Japan
4.4.7.2. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Type in Japan
4.4.7.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in Japan
4.4.7.4. Prevalent cases of Idiopathic Thrombocytopenic purpura (ITP) in Japan
4.4.7.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Japan
4.4.7.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in Japan
4.4.7.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Japan
4.4.7.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Japan
4.4.7.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in Japan
4.4.7.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Japan
4.4.7.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in Japan
4.4.7.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Japan

5. Appendix
5.1. Report Methodology

6. Capabilities

7. Disclaimer

8. About the Publisher

List of Tables
Table 1: First-Line Treatment Options for Immune Thrombocytopenia
Table 2: Second and Third-Line Treatment Options for Immune Thrombocytopenia
Table 3: Prevalent Population of Thrombocytopenia in 7MM (2016-2027)
Table 4: Prevalent Cases of Thrombocytopenia in the United States (2016-2027)
Table 5: Prevalent Cases of TTP by Type in the United States (2016-2027)
Table 6: Prevalent Cases of TTP by Age in the United States (2016-2027)
Table 7: Prevalent Cases of ITP in the United States (2016-2027)
Table 8: Prevalent cases of CIT in the United States (2016-2027)
Table 9: Prevalent cases of HIT in the United States (2016-2027)
Table 10: Prevalent cases of Thrombocytopenia associated with CLD in the United States (2016-2027)
Table 11: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in the United States (2016-2027)
Table 12: Diagnosed Cases of ITP in the United States (2016-2027)
Table 13: Diagnosed cases of CIT in the United States (2016-2027)
Table 14: Diagnosed cases of HIT in the United States (2016-2027)
Table 15: Diagnosed cases of Thrombocytopenia associated with CLD in the United States (2016-2027)
Table 16: Prevalent Cases of Thrombocytopenia in Germany (2016-2027)
Table 17: Prevalent Cases of TTP by Type in Germany (2016-2027)
Table 18: Prevalent Cases of TTP by Age in Germany (2016-2027)
Table 19: Prevalent Cases of ITP in Germany (2016-2027)
Table 20: Prevalent cases of CIT in Germany (2016-2027)
Table 21: Prevalent cases of HIT in Germany (2016-2027)
Table 22: Prevalent cases of Thrombocytopenia associated with CLD in Germany (2016-2027)
Table 23: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Germany (2016-2027)
Table 24: Diagnosed Cases of ITP in Germany (2016-2027)
Table 25: Diagnosed cases of CIT in Germany (2016-2027)
Table 26: Diagnosed cases of HIT in Germany (2016-2027)
Table 27: Diagnosed cases of Thrombocytopenia associated with CLD in Germany (2016-2027)
Table 28: Prevalent Cases of Thrombocytopenia in France (2016-2027)
Table 29: Prevalent Cases of TTP by Type in France (2016-2027)
Table 30: Prevalent Cases of TTP by Age in France (2016-2027)
Table 31: Prevalent Cases of ITP in France (2016-2027)
Table 32: Prevalent cases of CIT in France (2016-2027)
Table 33: Prevalent cases of HIT in France (2016-2027)
Table 34: Prevalent cases of Thrombocytopenia associated with CLD in France (2016-2027)
Table 35: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in France (2016-2027)
Table 36: Diagnosed Cases of ITP in France (2016-2027)
Table 37: Diagnosed cases of CIT in France (2016-2027)
Table 38: Diagnosed cases of HIT in France (2016-2027)
Table 39: Diagnosed cases of Thrombocytopenia associated with CLD in France (2016-2027)
Table 40: Prevalent Cases of Thrombocytopenia in Italy (2016-2027)
Table 41: Prevalent Cases of TTP by Type in Italy (2016-2027)
Table 42: Prevalent Cases of TTP by Age in Italy (2016-2027)
Table 43: Prevalent Cases of ITP in Italy (2016-2027)
Table 44: Prevalent cases of CIT in Italy (2016-2027)
Table 45: Prevalent cases of HIT in Italy (2016-2027)
Table 46: Prevalent cases of Thrombocytopenia associated with CLD in Italy (2016-2027)
Table 47: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Italy (2016-2027)
Table 48: Diagnosed Cases of ITP in Italy (2016-2027)
Table 49: Diagnosed cases of CIT in Italy (2016-2027)
Table 50: Diagnosed cases of HIT in Italy (2016-2027)
Table 51: Diagnosed cases of Thrombocytopenia associated with CLD in Italy (2016-2027)
Table 52: Prevalent Cases of Thrombocytopenia in Spain (2016-2027)
Table 53: Prevalent Cases of TTP by Type in Spain (2016-2027)
Table 54: Prevalent Cases of TTP by Age in Spain (2016-2027)
Table 55: Prevalent Cases of ITP in Spain (2016-2027)
Table 56: Prevalent cases of CIT in Spain (2016-2027)
Table 57: Prevalent cases of HIT in Spain (2016-2027)
Table 58: Prevalent cases of Thrombocytopenia associated with CLD in Spain (2016-2027)
Table 59: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Spain (2016-2027)
Table 60: Diagnosed Cases of ITP in Spain (2016-2027)
Table 61: Diagnosed cases of CIT in Spain (2016-2027)
Table 62: Diagnosed cases of HIT in Spain (2016-2027)
Table 63: Diagnosed cases of Thrombocytopenia associated with CLD in Spain (2016-2027)
Table 64: Prevalent Cases of Thrombocytopenia in the United Kingdom (2016-2027)
Table 65: Prevalent Cases of TTP by Type in the United Kingdom (2016-2027)
Table 66: Prevalent Cases of TTP by Age in the United Kingdom (2016-2027)
Table 67: Prevalent Cases of ITP in the United Kingdom (2016-2027)
Table 68: Prevalent cases of CIT in the United Kingdom (2016-2027)
Table 69: Prevalent cases of HIT in the United Kingdom (2016-2027)
Table 70: Prevalent cases of Thrombocytopenia associated with CLD in the United Kingdom (2016-2027)
Table 71: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in the United Kingdom (2016-2027)
Table 72: Diagnosed Cases of ITP in the United Kingdom (2016-2027)
Table 73: Diagnosed cases of CIT in the United Kingdom (2016-2027)
Table 74: Diagnosed cases of HIT in the United Kingdom (2016-2027)
Table 75: Diagnosed cases of Thrombocytopenia associated with CLD in the United Kingdom (2016-2027)
Table 76: Prevalent Cases of Thrombocytopenia in Japan (2016-2027)
Table 77: Prevalent Cases of TTP by Type in Japan (2016-2027)
Table 78: Prevalent Cases of TTP by Age in Japan (2016-2027)
Table 79: Prevalent Cases of ITP in Japan (2016-2027)
Table 80: Prevalent cases of CIT in Japan (2016-2027)
Table 81: Prevalent cases of HIT in Japan (2016-2027)
Table 82: Prevalent cases of Thrombocytopenia associated with CLD in Japan (2016-2027)
Table 83: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Japan (2016-2027)
Table 84: Diagnosed Cases of ITP in Japan (2016-2027)
Table 85: Diagnosed cases of CIT in Japan (2016-2027)
Table 86: Diagnosed cases of HIT in Japan (2016-2027)
Table 87: Diagnosed cases of Thrombocytopenia associated with CLD in Japan (2016-2027)

List of Figures
Figure 1: Cellular pathogenic mechanisms in immune thrombocytopenia (ITP)
Figure 2: Schematic representation of pathophysiology of cITP
Figure 3: Algorithm for management of thrombocytopenia
Figure 4: Diagnosis and treatment algorithm for Thrombotic microangiopathy
Figure 5: Diagnosis and treatment algorithm for Heparin-induced Thrombocytopenia
Figure 6: Direct Thrombin Inhibitor (DTI) Dosing and Monitoring
Figure 7: Prevalent Population of Thrombocytopenia in the 7MM (2016-2027)
Figure 8: Prevalent cases of Thrombocytopenia in the United States (2016-2027)
Figure 9: Prevalent cases of TTP by Type in the United States (2016-2027)
Figure 10: Prevalent cases of TTP by Age in the United States (2016-2027)
Figure 11: Prevalent Cases of ITP in the United States (2016-2027)
Figure 12: Prevalent cases of CIT in the United States (2016-2027)
Figure 13: Prevalent cases of HIT in the United States (2016-2027)
Figure 14: Prevalent cases of Thrombocytopenia associated with CLD in the United States (2016-2027)
Figure 15: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in the United States (2016-2027)
Figure 16: Diagnosed Cases of ITP in the United States (2016-2027)
Figure 17: Diagnosed cases of CIT in the United States (2016-2027)
Figure 18: Diagnosed cases of HIT in the United States (2016-2027)
Figure 19: Diagnosed cases of Thrombocytopenia associated with CLD in the United States (2016-2027)
Figure 20: Prevalent cases of Thrombocytopenia in Germany (2016-2027)
Figure 21: Prevalent cases of TTP by Type in Germany (2016-2027)
Figure 22: Prevalent cases of TTP by Age in Germany (2016-2027)
Figure 23: Prevalent Cases of ITP in Germany (2016-2027)
Figure 24: Prevalent cases of CIT in Germany (2016-2027)
Figure 25: Prevalent cases of HIT in Germany (2016-2027)
Figure 26: Prevalent cases of Thrombocytopenia associated with CLD in Germany (2016-2027)
Figure 27: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Germany (2016-2027)
Figure 28: Diagnosed Cases of ITP in Germany (2016-2027)
Figure 29: Diagnosed cases of CIT in Germany (2016-2027)
Figure 30: Diagnosed cases of HIT in Germany (2016-2027)
Figure 31: Diagnosed cases of Thrombocytopenia associated with CLD in Germany (2016-2027)
Figure 32: Prevalent cases of Thrombocytopenia in France (2016-2027)
Figure 33: Prevalent cases of TTP by Type in France (2016-2027)
Figure 34: Prevalent cases of TTP by Age in France (2016-2027)
Figure 35: Prevalent Cases of ITP in France (2016-2027)
Figure 36: Prevalent cases of CIT in France (2016-2027)
Figure 37: Prevalent cases of HIT in France (2016-2027)
Figure 38: Prevalent cases of Thrombocytopenia associated with CLD in France (2016-2027)
Figure 39: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in France (2016-2027)
Figure 40: Diagnosed Cases of ITP in France (2016-2027)
Figure 41: Diagnosed cases of CIT in France (2016-2027)
Figure 42: Diagnosed cases of HIT in France (2016-2027)
Figure 43: Diagnosed cases of Thrombocytopenia associated with CLD in France (2016-2027)
Figure 44: Prevalent cases of Thrombocytopenia in Italy (2016-2027)
Figure 45: Prevalent cases of TTP by Type in Italy (2016-2027)
Figure 46: Prevalent cases of TTP by Age in Italy (2016-2027)
Figure 47: Prevalent Cases of ITP in Italy (2016-2027)
Figure 48: Prevalent cases of CIT in Italy (2016-2027)
Figure 49: Prevalent cases of HIT in Italy (2016-2027)
Figure 50: Prevalent cases of Thrombocytopenia associated with CLD in Italy (2016-2027)
Figure 51: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Italy (2016-2027)
Figure 52: Diagnosed Cases of ITP in Italy (2016-2027)
Figure 53: Diagnosed cases of CIT in Italy (2016-2027)
Figure 54: Diagnosed cases of HIT in Italy (2016-2027)
Figure 55: Diagnosed cases of Thrombocytopenia associated with CLD in Italy (2016-2027)
Figure 56: Prevalent cases of Thrombocytopenia in Spain (2016-2027)
Figure 57: Prevalent cases of TTP by Type in Spain (2016-2027)
Figure 58: Prevalent cases of TTP by Age in Spain (2016-2027)
Figure 59: Prevalent Cases of ITP in Spain (2016-2027)
Figure 60: Prevalent cases of CIT in Spain (2016-2027)
Figure 61: Prevalent cases of HIT in Spain (2016-2027)
Figure 62: Prevalent cases of Thrombocytopenia associated with CLD in Spain (2016-2027)
Figure 63: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Spain (2016-2027)
Figure 64: Diagnosed Cases of ITP in Spain (2016-2027)
Figure 65: Diagnosed cases of CIT in Spain (2016-2027)
Figure 66: Diagnosed cases of HIT in Spain (2016-2027)
Figure 67: Diagnosed cases of Thrombocytopenia associated with CLD in Spain (2016-2027)
Figure 68: Prevalent cases of Thrombocytopenia in the United Kingdom (2016-2027)
Figure 69: Prevalent cases of TTP by Type in the United Kingdom (2016-2027)
Figure 70: Prevalent cases of TTP by Age in the United Kingdom (2016-2027)
Figure 71: Prevalent Cases of ITP in the United Kingdom (2016-2027)
Figure 72: Prevalent cases of CIT in the United Kingdom (2016-2027)
Figure 73: Prevalent cases of HIT in the United Kingdom (2016-2027)
Figure 74: Prevalent cases of Thrombocytopenia associated with CLD in the United Kingdom (2016-2027)
Figure 75: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in the United Kingdom (2016-2027)
Figure 76: Diagnosed Cases of ITP in the United Kingdom (2016-2027)
Figure 77: Diagnosed cases of CIT in the United Kingdom (2016-2027)
Figure 78: Diagnosed cases of HIT in the United Kingdom (2016-2027)
Figure 79: Diagnosed cases of Thrombocytopenia associated with CLD in the United Kingdom (2016-2027)
Figure 80: Prevalent cases of Thrombocytopenia in Japan (2016-2027)
Figure 81: Prevalent cases of TTP by Type in Japan (2016-2027)
Figure 82: Prevalent cases of TTP by Age in Japan (2016-2027)
Figure 83: Prevalent Cases of ITP in Japan (2016-2027)
Figure 84: Prevalent cases of CIT in Japan (2016-2027)
Figure 85: Prevalent cases of HIT in Japan (2016-2027)
Figure 86: Prevalent cases of Thrombocytopenia associated with CLD in Japan (2016-2027)
Figure 87: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Japan (2016-2027)
Figure 88: Diagnosed Cases of ITP in Japan (2016-2027)
Figure 89: Diagnosed cases of CIT in Japan (2016-2027)
Figure 90: Diagnosed cases of HIT in Japan (2016-2027)
Figure 91: Diagnosed cases of Thrombocytopenia associated with CLD in Japan (2016-2027)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll